For the first time since 2014, the American College of Obstetricians and Gynaecologists has updated its guidelines for the treatment of symptoms associated with menopause, reports NPR.
ACOG is now recommending hormone replacement therapy alongside certain antidepressants, non-hormonal medicines and other treatments to address symptoms like hot flushes, insomnia and mood swings.
“What’s changing is the breadth of options we now have … And the benefit of that is that we’re better equipped to be able to take an individualised approach for patients,” said Catherine Cansino, MD, MPH, an obstetrician/gynaecologist, chair of ACOG’s Committee on Clinical Practice Guidelines and co-author of the new guidance.
The guidance, released last week, focuses on specific menopausal symptoms and underscores that the safety of hormone replacement therapy is now “well-established”, Cansino said.
In 2002, the Women’s Health Initiative suggested that hormone replacement therapy increased the risk of heart disease, breast cancer, stroke and pulmonary embolism.
However, as researchers revisited that data years later, they noticed certain limitations, (including that most patients were 60 or older) making it difficult to generalise the findings to younger women experiencing menopause or perimenopause.
With more and better quality studies, physicians are able to review the evidence and make better-informed recommendations, Cansino said.
“Hormone therapy is probably the best option for symptomatic, newly menopausal women within 10 years of the final menstrual period or before 60,” said Robert Kauffman, MD, MSCP, a co-author of the guidelines.
In addition to hormone replacement therapy, the guidelines highlight new non-hormonal options for treating menopausal symptoms, including the drug fezolinetant, brand name Veozah, which the Food and Drug Administration approved to treat hot flushes in 2023 and elinzanetant, brand name Lynkuet, approved in 2025.
“What’s exciting about these options is they were specifically studied based on the understanding that we have of the physiology of thermoregulation and sleep,” Cansino said.
The medications work by blocking certain chemical messengers in the part of the brain that regulates body temperature and manages sleep/wake cycles, according to the guidance.
About 2m women begin menopause each year. The average age is 49.9, according to the guidelines. However, symptoms can begin years before that final menstrual period.
The new recommendations support the use of systemic hormone replacement therapy, or HRT, with a combination of oestrogen and progestogen in women with a uterus who have no contraindications to hormones.
Reasons to avoid hormone therapy include undiagnosed abnormal genital bleeding, and current or past histories of certain gynaecologic cancers, blood clots, stroke, heart attack, liver disease or a known or suspected pregnancy.
The reason progestogen is recommended in women with a uterus is because oestrogen can stimulate growth of the uterine lining and increase the risk of endometrial cancer. Progestogen therapy helps mitigate that risk, Cansino explained.
Around half a million women have hysterectomies each year, and for women without a uterus, ACOG recommends oestrogen alone.
As an alternative to oestrogen-progestogen therapy, ACOG also recommends a pill, sold under the brand name Duavee, that combines oestrogen and a drug called bazedoxifene. Bazedoxifene is a “selective oestrogen receptor modulator”, which blocks the oestrogen from working in certain areas of the body, such as breast tissue, while mimicking oestrogen's benefit for bone density, for instance.
Another drug recommended in the new guideline is gabapentin, an anticonvulsant typically used to treat seizures. It can also manage menopause symptoms for women who can’t tolerate hormones or the other new medicines.
Cognitive behavioural therapy, mindfulness-based interventions, exercise, clinical hypnosis, and acupuncture can all improve some symptoms, ACOG says, however the guidelines also note that the evidence for these interventions is weaker than the evidence for HRT.
Still, patients may have their own preferences and goals, Cansino said.
On whether she recommended one medication or tool over another, she warned against” over-simplifying treatment based on tiers”.
Just as with contraception, she noted that patients may choose a certain method, knowing that it's less effective. “As long as they understand the pros and cons, such a decision is perfectly OK.”
Meanwhile, demand for HRT is already rising. Last year, the FDA scrapped the “black box warning” on labels for certain oestrogen therapies.
In recent months, oestrogen products like transdermal patches have been hard for pharmacies to keep in stock.
“I think the shortage of transdermal oestrogen therapy highlights the fact that we have all of this attention about hormone therapy, and not necessarily enough about other treatment options,” Cansino told NPR.
She also stressed the need for patients to talk to trusted clinicians about the pros and cons of treatments and to avoid having “tunnel vision” about a single option.
The level of care that OB/GYNs provide by helping individual patients find the right treatment is one of the most important aspects of the new guidance, Cansino said.
“There’s a lot of misinformation out there and exaggerated claims about hormone therapy, and so some people end up taking risks when they shouldn’t,” she added.
See more from MedicalBrief archives:
Criticism over updated menopause guidelines
Hormones safe for menopause – US study dispels old flawed findings
Education needed regarding efficacy of HRT for most women